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The human microbiome, especially in
the intestinal tract has received increased
attention in the past few years due to its
importance in numerous biological pro-
cesses. Recent advances in DNA sequenc-
ing technology and analysis now allow us
to better determine global differences in
the composition of the gut microbial
population, and ask questions about its
role in health and disease. Thus far, roles
of these commensal bacteria on nutrient
acquisition, vitamin production, and intes-
tinal development have been identified
[1]. Furthermore, resistance or suscepti-
bility to a number of diseases, including
inflammatory bowel disease, obesity, en-
teric infections, and most recently ectopic
diseases, have been linked to the intestinal
microbiota [1,2]. Data on the mechanisms
through which the intestinal microbiota
impacts host immune development have
also begun to emerge [2]. The impact of
the intestinal microbiota on host physiol-
ogy is undeniable, and experiments using
germ-free, mono-, and poly-colonized
mice have addressed many aspects of the
microbiota’s influence on the mammalian
immune system.
Despite all the increased attention on
the interface between the microbiota and
host immune responses, it is still unclear
whether these commensal bacteria affect
the efficacy of vaccines. Due to its impact
in the development of immune function,
both in the gut and other organs, it is
reasonable to consider that the intestinal
microbiota will significantly affect how
individuals respond to vaccine antigens
[3,4]. For example, segmented filamentous
bacteria present in the intestinal microbi-
ota have been shown to induce maturation
of intestinal T cell adaptive functions [5].
Moreover, it has been shown that the
intestinal microbiota exerts a profound
effect on the metabolism of certain drugs
and toxins [1,6], and this may also indicate
that oral vaccines could be differentially
processed by the body depending on
variations in microbial communities be-
tween individuals. Hence, the microbiota
could be an underappreciated yet impor-
tant player to consider in the development
of vaccines, and also may help explain
some of the discrepancies observed in
vaccine efficacy in different populations
around the world.
Clinical trials testing the efficacy of oral
vaccines against polio, rotavirus, and
cholera have showed a lower immunoge-
nicity of these vaccines in individuals from
developing countries when compared to
individuals from the developed world [7–
11]. Clinical trials for a killed oral cholera
vaccine in Swedish and Nicaraguan chil-
dren have also shown blunted antibody
responses in Nicaraguan children com-
pared to Swedish children [11]. In a study
testing a live cholera oral vaccine, Lagos
and colleagues [12] demonstrated that
excessive bacterial growth in the small
intestine of children in less developed
countries might contribute to the low
antibody response to the vaccine. Different
vaccine strains of Shigella flexneri also
showed differential protection on individ-
uals from developing countries. In a study
testing Bangladeshi adults and children,
no significant immune response to this
vaccine was mounted, although the same
antigen was reactogenic in North Ameri-
can individuals [13]. Altogether, these
data highlight that individuals from differ-
ent parts of the world can mount different
immune responses to the same vaccine.
Several hypotheses that may explain this
phenomenon exist. For instance, socioeco-
nomic conditions, nutritional status, host
genetics, and earlier exposure to related
microorganisms are some of the aspects
that could contribute to the disparity in the
vaccine efficacies in different populations.
However, one poorly explored possibility
is that the composition of the intestinal
microbiota of these individuals may also
be a determining factor of vaccine efficacy.
In a way analogous to the hygiene hypo-
thesis [14], which states that reduced
exposure to microorganisms at an early
age may lead to increased susceptibility
to allergies, it is possible that the gut
microbiota of individuals with increased
exposure to microorganisms (and therefore
antigens) make them more tolerant to
vaccination, being unable to mount a
proper response compared to individuals
living in better socioeconomic conditions.
Discerning the effects of genetic and
environmental factors on vaccine efficacy
is a challenging task. Large clinical trials
involving individuals from different areas
of the world will likely be required to shed
light on whether the blunt immune res-
ponses to some of the oral vaccines men-
tioned herein are a consequence of genetic
factors or environmental variations, such
as the gut microbial community. Studies
involving immigrant volunteers could be
useful in addressing this issue by providing
a clear distinction between the effects of
genetics and the environment. Although
this is still an open question, data in the
literature suggest a more direct link
between the intestinal microbiota compo-
sition and the development of immune
responses to certain vaccine antigens. For
instance, the use of antibiotics in chickens
has been shown to increase the antibody
response following immunization [15].
Because antibiotic treatment will have
profound effects on the intestinal microbi-
ota, it is tempting to hypothesize that the
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important players in their immunological
response to the vaccine antigens. Further-
more, certain probiotic strains have been
shown to enhance antibody responses to
oral vaccines against rotavirus [16], Sal-
monella [17], polio [18], and cholera [19] in
human volunteers, and this effect was
observed after a short period (1–5 weeks)
of probiotic treatment. The positive effect
of probiotics on immune responses was
also seen in parenterally administered
vaccines against diphtheria, tetanus, Hae-
mophilus influenzae type B, and hepatitis B
[20–22] in infants after a 6-month period.
Because of the number of licensed oral-
administered human vaccines available is
limited, studies on how the intestinal
microbiota affect parenterally adminis-
tered human vaccines would have a more
significant impact on human health.
However, in all studies cited above, there
was no long-term follow-up on the en-
hanced effects of the probiotics on vaccine
efficacy. Additionally, more detailed stud-
ies on the establishment of the probiotic
strains within the resident microbiota will
be required to establish minimal doses and
treatment regimens, important aspects
that need to be addressed if the microbiota
is to be considered in vaccine development
in the future. It has also been suggested
that prebiotics, which are compounds that
can enhance the proliferation of certain
commensals, can enhance the efficacy of
oral vaccines. Recently, a well-studied
fructo-oligosaccharide prebiotic has been
shown to improve the efficacy of a vaccine
against Salmonella infection [23]. In this
study, administration of the prebiotic prior
to vaccination improved host responses
and rates of protection against infection in
mice. Unfortunately, the authors were
unable to show significant changes in
microbiota composition, possibly due to
the lack of detailed analyses. In another
study, Vos et al. [24] showed that a
prebiotic mixture containing galacto- and
fructo-oligosaccharides enhanced systemic
adaptive immune responses in a murine
influenza vaccination model. In this case,
increased proportions of certain members
of the microbiota could be observed,
suggesting a role for the microbial com-
munity in the increased host immune
response.
Although some studies indicate that the
microbiota may play an important role in
vaccine efficacy, this area of research is still
in its infancy. For instance, the mecha-
nisms involved in the pro- and prebiotic
enhancement of vaccine efficacy mentioned
above are largely unknown. Nevertheless,
current knowledge of the effect of the
intestinal microbiota on the development
of not only local but also systemic immune
functions provides a direct link between
commensal populations in the intestine and
immune responses to vaccine antigens [3,4].
We now have the tools to study and take
advantage of what the microbiota has to
offer in order to enhance host responses
to vaccines, with the use of probiotics or
prebiotics as adjuvants. Studies using ani-
mal models with defined intestinal microbi-
al communities can be helpful to evaluate
the effect of intestinal commensals on the
immune response to vaccines. However,
animal models can only partially elucidate
this issue and, although cumbersome,
studies in human volunteers will be essential
in defining the effect of commensals in
vaccine efficacy. We suggest that the study
of the relationships between individual
commensal populations of humans and
responses to vaccines will be instrumental
in our quest to improve general vaccine
development. By taking into consideration
the microbial populations of geographically
diverse groups of individuals, we may be
ableto develop better-targeted vaccinesthat
will improve protection against multiple
pathogens.
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